American Oriental Bioengineering Forms Science and Technology Advisory Committee

NEW YORK, May. 20 /PRNewswire/ --

NEW YORK, May 20 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. ("AOB" or "the Company"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced the formation of a Science and Technology Advisory Committee ("STAC") to bring together experts from the pharmaceutical, biotechnology, pharmacology, drug safety, clinical affairs and financial services industries. The STAC will meet regularly to discuss and oversee AOBO's long-term growth strategy. The meeting was held today in Beijing, China.

The committee includes professionals who have worked in a variety of healthcare research, development and strategic roles at companies such as SmithKline Beecham, Schering-Plough Research Institute, Novartis Pharma AG, and IMS Health. The committee also includes proven scientists and professors from China's research and development fields from institutions such as China's Drug Safety Evaluation Center, the State Food and Drug Administration, Chinese Academy of Engineering specializing in Traditional Chinese Medicine, Chinese Academy of Medical Sciences, Tsinghua University and the Institute of Medicinal Plant Development.

Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, stated, "We are delighted to welcome these renowned professionals to our Science and Technology Advisory Committee and we look forward to building on their expertise as we pursue our long-term goal to be a top five pharmaceutical company in China. Each member brings unique insight and relationships to AOBO, and their unparalleled experience should ultimately strengthen our development plan," concluded Mr. Liu.

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China. For more information, visit http://www.bioaobo.com.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2007, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.